Manhattan, NY- April 24, 2014 – (Techsonian) – Geron Corporation, (NASDAQ:GERN) a clinical stage biopharmaceutical company, develops a telomerase inhibitor, imetelstat, to treat hematologic myeloid malignancies. The company was founded in 1990 and is based in Menlo Park, California.
Geron Corporation (NASDAQ:GERN) ended lower -8.68% and complete the day at $2.00. The total number of shares changed hands during the day was 3.78 million. After opening at $2.17, the stock hit as high as $2.20. However, it traded between $1.05 and $7.79 over the last twelve months.
Has GERN Found The Bottom and Ready To Move Up? Find Out Here
MannKind, (NASDAQ: MNKD) stated that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) date for AFREZZA(R) by three months to July 15, 2014 in order to provide time for a full review of information submitted by MannKind in response to the FDA’s requests.
MannKind Corporation (NASDAQ:MNKD) closed yesterday at $6.36, a -1.40% decrease. Around 3.76 million shares were exchanged during the last trade, while the average volume is about 14.33 million shares. The company is now valued at around $2.45 billion.
Has MNKD Found The Bottom And Ready To Gain Momentum? Find Out Here
Gevo, (NASDAQ:GEVO) recently declared its financial outcome for the three months ended December 31, 2013 and provided an update on recent corporate highlights. The Company is focused on the development and commercialization of alternatives to petroleum-based products.
Gevo, Inc. (NASDAQ:GEVO) moved -7.63 percent lower at $1.09 and traded between $1.04 and $1.23 after opening the day at $1.16. Its performance over the last five days remained -2.24%, which stands at -17.42% for a month. Going back further than one month, 1-year performance after recent close was -23.24%.
Why Should Investors Buy GEVO After the Recent Fall? Just Go Here and Find Out
Eldorado Gold Corp (USA) (NYSE:EGO) offer an update on its Deva Gold SA Certej project in Romania (the “Certej Project” or the “Project”). A NI-43-101 Technical Report (“TR”) which includes findings of an updated prefeasibility study (“PFS”) was filed April 7th 2014 on SEDAR and EDGAR.
Eldorado Gold Corp (USA) (NYSE:EGO) shares rose, gaining 0.51 percent to close at $5.95. The stock is around 7.79% this year and -15.6% for the last 12 months. The stock traded on a volume of 3.58 million shares and the average volume of the stock remained 5.44 million shares.
Will EGO Get Buyers Even After The Recent Rally? Find Out Here